Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents

S Miyamoto, N Miyake, LF Jarskog… - Molecular …, 2012 - nature.com
Since the introduction of chlorpromazine and throughout the development of the new-
generation antipsychotic drugs (APDs) beginning with clozapine, the D 2 receptor has been …

Serotonin controlling feeding and satiety

JP Voigt, H Fink - Behavioural brain research, 2015 - Elsevier
Serotonin has been implicated in the control of satiety for almost four decades. Historically,
the insight that the appetite suppressant effect of fenfluramine is linked to serotonin has …

Amygdala plasticity and pain

JM Thompson, V Neugebauer - Pain Research and …, 2017 - Wiley Online Library
The amygdala is a limbic brain region that plays a key role in emotional processing,
neuropsychiatric disorders, and the emotional‐affective dimension of pain. Preclinical and …

[HTML][HTML] The serotonergic system and cognitive function

D Švob Štrac, N Pivac, D Mück-Šeler - Translational neuroscience, 2016 - degruyter.com
Symptoms of cognitive dysfunction like memory loss, poor concentration, impaired learning
and executive functions are characteristic features of both schizophrenia and Alzheimer's …

Serotonin receptors in depression and anxiety: Insights from animal studies

E Żmudzka, K Sałaciak, J Sapa, K Pytka - Life sciences, 2018 - Elsevier
Serotonin regulates many physiological processes including sleep, appetite, and mood.
Thus, serotonergic system is an important target in the treatment of psychiatric disorders …

Head‐twitch response in rodents induced by the hallucinogen 2, 5‐dimethoxy‐4‐iodoamphetamine: a comprehensive history, a re‐evaluation of mechanisms, and its …

CE Canal, D Morgan - Drug testing and analysis, 2012 - Wiley Online Library
Two primary animal models persist for assessing hallucinogenic potential of novel
compounds and for examining the pharmacological and neurobiological substrates …

Neurochemical and molecular characterization of ketamine-induced experimental psychosis model in mice

M Chatterjee, R Verma, S Ganguly, G Palit - Neuropharmacology, 2012 - Elsevier
Ketamine, an NMDA receptor antagonist has been shown to induce aberrant behaviour
phenotypes in rodents, some of which are known to simulate the behaviour abnormalities …

New therapeutic opportunities for 5-HT2C receptor ligands in neuropsychiatric disorders

G Di Giovanni, P De Deurwaerdère - Pharmacology & therapeutics, 2016 - Elsevier
Abstract The 5-HT 2C receptor (R) displays a widespread distribution in the CNS and is
involved in the action of 5-HT in all brain areas. Knowledge of its functional role in the CNS …

The role of serotonin in cognitive function: evidence from recent studies and implications for understanding depression

P Cowen, AC Sherwood - Journal of psychopharmacology, 2013 - journals.sagepub.com
Background: Symptoms of cognitive impairment such as poor concentration, memory loss
and difficulty with decision making are prevalent in patients with depression, but currently …

[HTML][HTML] The use of risperidone in behavioral and psychological symptoms of dementia: a review of pharmacology, clinical evidence, regulatory approvals, and off …

I Yunusa, ML El Helou - Frontiers in Pharmacology, 2020 - frontiersin.org
Dementia represents a global health challenge due to the increase in elderly population
worldwide. In addition to memory loss, dementia often results in severe behavioral and …